The first 2 authors contributed equally to this article.
Identification of novel germline polymorphisms governing capecitabine sensitivity
Article first published online: 3 JAN 2012
Copyright © 2011 American Cancer Society
Volume 118, Issue 16, pages 4063–4073, 15 August 2012
How to Cite
O'Donnell, P. H., Stark, A. L., Gamazon, E. R., Wheeler, H. E., McIlwee, B. E., Gorsic, L., Im, H. K., Huang, R. S., Cox, N. J. and Dolan, M. E. (2012), Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer, 118: 4063–4073. doi: 10.1002/cncr.26737
- Issue published online: 3 AUG 2012
- Article first published online: 3 JAN 2012
- Manuscript Accepted: 7 OCT 2011
- Manuscript Revised: 5 OCT 2011
- Manuscript Received: 19 AUG 2011
Capecitabine, an oral 5-fluorouracil (5-FU) prodrug, is widely used in the treatment of breast, colorectal, and gastric cancers. To guide the selection of patients with potentially the greatest benefit of experiencing antitumor efficacy, or, alternatively, of developing toxicities, identifying genomic predictors of capecitabine sensitivity could permit its more informed use.
The objective of this study was to perform capecitabine sensitivity genome-wide association studies (GWAS) using 503 well genotyped human cell lines from individuals representing multiple different world populations. A meta-analysis that included all ethnic populations then enabled the identification of novel germline determinants (single nucleotide polymorphisms [SNPs]) of capecitabine susceptibility.
First, an intrapopulation GWAS of Caucasian individuals identified reference SNP 4702484 (rs4702484) (within adenylate cyclase 2 [ADCY2]) at a level reaching genome-wide significance (P = 5.2 × 10−8). This SNP is located upstream of the 5 methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR) gene, and it is known that the enzyme for MTRR is involved in the methionine-folate biosynthesis and metabolism pathway, which is the primary target of 5-FU-related compounds, although the authors were unable to identify a direct relation between rs4702484 and MTRR expression in a tested subset of cells. In the meta-analysis, 4 SNPs comprised the top hits, which, again, included rs4702484 and 3 additional SNPs (rs8101143, rs576523, and rs361433) that approached genome-wide significance (P values from 1.9 × 10−7 to 8.8 × 10−7). The meta-analysis also identified 1 missense variant (rs11722476; serine to asparagine) within switch/sucrose nonfermentable-related, matrix-associated, actin-dependent regulator of chromatin (SMARCAD1), a novel gene for association with capecitabine/5-FU susceptibility.
Toward the goal of individualizing cancer chemotherapy, the current study identified novel SNPs and genes associated with capecitabine sensitivity that are potentially informative and testable in any patient regardless of ethnicity. Cancer 2011. © 2011 American Cancer Society.